子宫内膜癌患者血清hsa-miR-155的表达及其临床意义  

Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer

作　　者：谭志琴 刘伏香 唐海林[2] 苏琦[2] 

机构地区：[1]解放军第一六九医院妇产科,湖南省衡阳421002 [2]南华大学肿瘤研究所

出　　处：《中华妇产科杂志》2010年第10期772-774,共3页Chinese Journal of Obstetrics and Gynecology

基　　金：国家自然科学基金（30600285）

摘　　要：目的 探讨hsa-miR-155在子宫内膜癌患者血清中的表达及其临床意义.方法 选择2008年9月至2009年12月间解放军第一六九医院妇产科收治的44例子宫内膜癌患者,以同期12例健康志愿者作为对照,应用实时荧光定量PCR技术检测子宫内膜癌患者和健康志愿者血清hsa-miR-155的表达水平（以倍数表示）,分析hsa-miR-155表达与子宫内膜癌临床病理指标间的关系.结果 相对于健康志愿者,子宫内膜癌患者血清hsa-miR-155的表达水平为（3.9±0.7）倍,两者比较,差异有统计学意义（P＜0.01）.其中,高、中、低分化子宫内膜癌患者血清hsa-miR-155的表达水平分别为（3.7±0.6）、（3.9±0.6）、（3.7±0.6）倍,3者分别比较,差异均无统计学意义（P＞0.05）;子宫内膜样腺癌与非子宫内膜样腺癌患者血清hsa-miR-155的表达水平分别为（3.8±0.6）、（3.9±0.6）倍,两者比较,差异无统计学意义（P＞0.05）;Ⅰ～Ⅱ、Ⅲ～Ⅳ期子宫内膜癌患者血清hsa-miR-155的表达水平分别为（2.1±0.4）、（5.6±0.8）倍,两者比较,差异有统计学意义（P＜0.01）;有、无盆腔淋巴结转移子宫内膜癌患者血清hsa-miR-155的表达水平分别为（5.5±0.5）、（1.9±0.2）倍,两者比较,差异有统计学意义（P＜0.01）.结论 hsa-miR-155与子宫内膜癌的发生、转移密切相关,有可能成为判断子宫内膜癌疗效及预后的潜在生物学指标.Objective To investigate the expression of the hsa-miR-155 in serum of endometrial cancer and its clinical significance. Methods Collected 44 cases blood specimens before surgery operation from Sep. 2008 to Dec. 2009, and collected 12 cases blood specimens from the health of volunteers in comparison. Real time quantity PCR was used to detect the expression of hsa-miR-155 in those specimens and analyzed clinical pathological with the expression of hsa-mir-155 in endometrial cancer. Results The expression of hsa-miR-155 was （3.9 ±0.7） in endometrial cancer, which was significantly higher than that in control group（ P ＜ 0.01 ）. The expressions of hsa-miR-155 were （ 3.7 ± 0.6 ）, （ 3.9 ± 0.6 ） and （ 3.7 ±0.6）times in well, moderately and poorly differentiated endometrial cancer, respectively,while there were not significant difference （ P ＞ 0.05 ）. The expressions were （ 3.8 ± 0.6 ） and （ 3.9 ± 0.6 ） times between endometrioid adenocarcinoma and non-endometrioid adenocarcinoma, and there were significant difference （P ＞ 0.05）. The expressions were （ 2.1 ± 0.4 ） and （ 5.6 ± 0.8 ） times in stage Ⅰ - Ⅱ and Ⅲ - Ⅳ endometrial cancer, respectively, in which there were significant difference （P ＜ 0.05 ）. The expressions of hsa-miR-155 were （5.5 ± 0.5 ） and （ 1.9 ± 0.2） times between lymph node metastasis and without lymph node metastasis in endometrial cancer, in which there were significant difference （P ＜ 0.01 ）. Conclusion Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker.

关 键 词：子宫内膜肿瘤 微RNAS 聚合酶链反应 

分 类 号：R686[医药卫生—骨科学]